Magenta Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Dianthus Therapeutics

03/08/2023 14:59

* Magenta Therapeutics Inc  MGTA.OQ  reported a quarterly
adjusted
loss of 5 cents​​ per share for the quarter ended in June. The
mean expectation of two analysts for the quarter was for a loss
of 19 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Magenta Therapeutics Inc's reported EPS for the quarter
was a
loss of 5 cents​.
    * The mean earnings estimate of analysts had risen by
about 32.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Magenta Therapeutics Inc shares had risen by 6.5% this
quarter and gained 104.3% so far this year.
    * The company reported a quarterly loss of $3.28 million.
    * Wall Street's median 12-month price target for Magenta
Therapeutics Inc is $1.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 3 at 01:58 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.19          -0.05          Beat
 Mar. 31 2023      -0.41          -0.48          Missed
 Dec. 31 2022      -0.27          -0.34          Missed
 Sep. 30 2022      -0.30          -0.27          Beat